Christensen S, Shalmi M, Hansen A K, Marcussen N
Department of Pharmacology, Panum Institute, University of Copenhagen, Denmark.
Pharmacol Toxicol. 1997 Mar;80(3):132-41. doi: 10.1111/j.1600-0773.1997.tb00386.x.
Administration of lithium in the diet to new-born rats induces chronic renal failure associated with hypertension, proteinuria and irreversible tubulo-interstitial morphological changes. In the present study we induced chronic renal failure by administration of lithium for 16 weeks to new-born rats, and examined the spontaneous course of this nephropathy and the effects of antihypertensive treatment with either perindopril (12 mg/kg diet) or hydrochlorothiazide (500-1000 mg/kg diet) during a 24 weeks follow up period without lithium. In the placebo group, progression to terminal uraemia occurred in all rats with severe renal failure (initial Purea > 15 mM) (10 of 18). Rats with mild-moderate renal failure (Purea 9-15 mM) showed no deterioration in renal function despite persistent systolic hypertension and irreversible structural renal changes. Perindopril normalized the blood pressure in all rats but did not prevent the progression to terminal uraemia (8 to 18). Hydrochlorothiazide partially controlled the hypertension and accellerated the progression of uraemia without increasing the mortality (7 of 17). Irrespective of treatments, the predominant quantitative structural changes (e.g. decreased volume of proximal tubular cells) showed significant correlations with the degree of renal dysfunction, but not with systolic blood pressure in the surviving rats. It is concluded that progression of lithium-induced nephropathy to terminal uraemia occurs when the nephrotoxic insult results in a more than 50% reduction of the glomerular filtration rate, judged from Purea levels. The failure of effective antihypertensive treatment with an angiotension-converting enzyme inhibitor to modify the progression suggests that in this model, systemic or glomerular hypertension may not be an important pathophysiological factor. The structural and functional deterioration observed in Li-uraemic rats during treatment with hydrochlorothiazide remains unexplained.
给新生大鼠喂食锂可导致与高血压、蛋白尿和不可逆的肾小管间质形态学改变相关的慢性肾衰竭。在本研究中,我们给新生大鼠喂食锂16周以诱导慢性肾衰竭,并在随后24周不喂食锂的期间,检查了这种肾病的自然病程以及培哚普利(12毫克/千克饮食)或氢氯噻嗪(500 - 1000毫克/千克饮食)进行降压治疗的效果。在安慰剂组中,所有患有严重肾衰竭(初始血尿素氮>15毫摩尔)的大鼠(18只中的10只)都进展为终末期尿毒症。患有轻 - 中度肾衰竭(血尿素氮9 - 15毫摩尔)的大鼠尽管持续存在收缩期高血压和不可逆的肾脏结构改变,但肾功能并未恶化。培哚普利使所有大鼠的血压恢复正常,但并未阻止进展为终末期尿毒症(8只至18只)。氢氯噻嗪部分控制了高血压并加速了尿毒症的进展,但未增加死亡率(17只中的7只)。无论治疗如何,主要的定量结构变化(如近端肾小管细胞体积减小)与存活大鼠的肾功能障碍程度显著相关,但与收缩压无关。得出的结论是,从血尿素氮水平判断,当肾毒性损伤导致肾小球滤过率降低超过50%时,锂诱导的肾病会进展为终末期尿毒症。用血管紧张素转换酶抑制剂进行有效的降压治疗未能改变疾病进展,这表明在该模型中,全身性或肾小球性高血压可能不是一个重要的病理生理因素。氢氯噻嗪治疗期间锂诱导的尿毒症大鼠中观察到的结构和功能恶化原因仍未明。